<DOC>
	<DOCNO>NCT00570882</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , feasibility sunitinib 4/2 2/1 regimen previously untreated metastatic RCC select promise regimen , use study patient population .</brief_summary>
	<brief_title>Study Sunitinib Administered 4/2 vs. 2/1 Schedule Advanced Renal Cell Carcinoma ( RCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1 . Histologically cytologically confirmation renal cell carcinoma clear cell histologic component 2 . Patients must present stage IV disease amenable surgery , radiotherapy , combine modality therapy curative intent . 3 . Measurable disease accord RECIST criterion require patient evaluable lesion without measurable lesion allow enrol study 4 . ECOG performance status 2 well 5 . Age 18 year old 6 . Adequate bone marrow , hepatic , renal function 7 . Life expectancy &gt; 3 month 8 . Singed date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrollment 1 . Known spinal cord compression carcinomatous meningitis 2 . Diagnosis serious secondary malignancy within last 2 year , except adequately treat basal cell squamous cell carcinoma skin , situ carcinoma cervix uteri 3 . Hypertension control medication ( blood pressure &gt; 150/90 mmHg despite optimal medical therapy ) 4 . Treatment anticonvulsant agent treatment therapeutic dos coumadin currently within 2 week prior first day sunitinib administration . Low dose coumadin DVT prophylaxis permit ( 2 mg/day ) . 5 . Pregnancy breast feed . 6 . Other severe acute chronic medical psychiatric condition 7 . Prior treatment sunitinib , sorafenib , bevacizumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Renal cell carcinoma</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>phase II study</keyword>
	<keyword>Randomized study</keyword>
</DOC>